The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...

The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca posted increased core earnings per share and sales for the first quarter but warned of mounting legal challenges in China.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said ... as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these will feature in the ASCO 2025 plenary ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.